AstraZeneca and Baxdrostat unveil promising new treatments for resistant hypertension
TL;DR Summary
AstraZeneca plans to seek regulatory approval for its experimental blood pressure drug, baxdrostat, by the end of the year, aiming for potential approval in 2026 in the US and EU. The drug targets the hormone aldosterone and has shown promising results in reducing systolic blood pressure, with peak sales expected to exceed $5 billion. A small percentage of patients experienced hyperkalaemia.
- AstraZeneca to seek approval for blood pressure drug by year-end Reuters
- There may soon be a new approach to treat hard-to-control high blood pressure CNN
- New drug hailed as ‘gamechanger’ in tackling stubbornly high blood pressure The Guardian
- BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension TCTMD.com
- New blood pressure pill ‘lowers risk of heart problems in 12 weeks’ The Independent
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 2 min read
Condensed
84%
381 → 61 words
Want the full story? Read the original article
Read on Reuters